The dilemma of hyperoxia following positive pressure mechanical ventilation: Role of iron and the benefit of iron chelation with deferasirox

European Review for Medical and Pharmacological Sciences

Volumn 15, Issue 10, 2011, Pages 1141-1148

  Mousavi, S ^a   Abdollahi, M ^a   Ahmadi, A ^b   Najafi, A ^b   Pazouki, M ^b   Hadjibabaie, M ^a   Ziaee, S ^a   Hamishehkar, H ^c   Kebriaeezadeh, A ^a   Mojtahedzadeh, Mojtaba ^a  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Deferasirox; Hyperoxia; Iron; Iron chelator; Lung injury

Indexed keywords

8 HYDROXYGUANINE; 8 ISOPROSTANE; CARBONYL DERIVATIVE; DEFERASIROX; FERRITIN; IRON; OXYGEN; TRANSFERRIN;

ADULT; ARTICLE; BRONCHOSCOPY; CLINICAL ARTICLE; FEMALE; HUMAN; HYPEROXIA; IRON CHELATION; IRON METABOLISM; LUNG INJURY; LUNG LAVAGE; MALE; OXIDATIVE STRESS; OXYGEN THERAPY; POSITIVE END EXPIRATORY PRESSURE; PROTEIN BLOOD LEVEL;

ADULT; BENZOIC ACIDS; FEMALE; FERRITINS; HUMANS; HYPEROXIA; IRON; IRON CHELATING AGENTS; LUNG INJURY; MALE; MIDDLE AGED; OXIDATIVE STRESS; POSITIVE-PRESSURE RESPIRATION; TRIAZOLES;

EID: 82455186197     PISSN: 11283602     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (46)

1. FRIDOVICH I. Oxygen toxicity: A radical explanation. J Exp Biol 1998; 201: 1203-1209.
2. CHOW CH, ABREU M, SUZUKI T, DOWNEY G. Oxidative stress and acute lung injury. Am J Respir Cell Mol Biol 2003; 29: 427-431.
3. ALTEMEIR W, SINCLAIR S. Hyperoxia in the intensive care unit: why more is not always better. Curr Opin Crit Care 2007; 13: 73-78.
4. PATEL D, GOEL A, AGRAWAL SB, GARY P, LAKHANI K. oxygen toxicity. JIAMC 2003; 4: 234-237.
5. MORGAN A. The pulmonary toxicity of oxygen. Anesthesiology 1968; 29: 570-579.
6. VAN DE VLIET A, CROSS C. Oxidants, nitrosants and the lung. Am J Med 2000; 109: 398-421.
7. BARAZZONE C, HOROWITZ S, DONATE YR, RODRIGUEZ I, PIGUET PF. Oxygen toxicity in mouse lung: pathway to death. Am J Respir Cell Mol Biol 1998; 19: 573-581.
8. MCCORD JM. Iron, free radicals and oxidative injury. Semin Hematol 1998; 35: 5-12.
9. EMERIT J, BEAUMONT C, TRIVIN F. Iron metabolism, free radicals and oxidative injury. Biomed Pharmacother 2001; 55: 333-339.
10. GUTTERIDGE JMC. Iron and oxygen: a biologically damaging mixture. Acta Paediatr Scand Suppl 1989; 361: 78-85.
11. GUTTERIDGE JMC, MUMBY S, QUINLAN GJ, CHUNG KF, EVANS TW. Pro-oxidant iron is present in human pulmonary epithelial lining fluid: implications for oxidative stress in lung. Biochem Biophys Res Commun 1996; 220: 1024-1027.
12. UPTON RL, CHEN Y, MUMBY S, GUTTERIDGE JMC, ANNING PB, NICHOLSON AG, EVANS TW, QUINLAN GJ. Variable tissue expression of transferrin receptors: relevance to ARDS. Eur Repir J 2003; 22: 335-341.
13. GUTTERIDGE JMC, QUINLAN G, MUMBY S, HEATH A, EVANS T. Primary plasma antioxidants in adult respiratory distress syndrome patients: Changes in iron-oxidizing, iron-binding, and free radical-scavenging proteins. J Lab Clin Med 1994; 124: 263-273.
14. SHARKEY R, DONNELLY S, CONNELLY K, ROBERTSON C, HASLEH CH, ROPINE J. Initial serum ferritin levels in patients with multiple trauma and the subsequent development of ARDS. Am J Respir Crit Care Med 1999; 159: 1506-1509.
15. WESSELIUS L, WADE W, BAILY K, VAMOS S, O'BRIEN-LANDER A, WEIGMANN TH. Iron uptake promotes hyperoxic injury to alveolar macrophages.Am J Respir Crit Care Med 1996; 159: 100-106.
16. HALLMAN M, SARNESTO A, BRY K. Interaction of transferrin saturated with iron with lung surfactant in respiratory failure. J Appl Physiol 1994; 77: 757-766.
17. FOGG S, AGRAWAL A, NICK H, VISNER G. Iron regulates hyperoxia-dependent human heme oxygenase 1 gene expression in pulmonary endothelial cell. Am J Respir Cell Mol Biol 1999; 20: 794-804.
18. DENNERY PH, SPITZ D, YANG G, TATAROV A, LEE CH, SHEGOG M. Oxygen toxicity and iron accumulation in the lungs of mice lacking heme oxygenase-2. J Clin Invest 1998; 101: 1001-1011.
19. HARRISON PM, AROSIO P. The ferritins: molecular properties, iron storage, function, and cellular regulation. Biochim Biophys Acta 1996; 1275: 161-203.
20. TURI J, YANG F, GARRICK M, PIANTADOSI C, GHIO A. The iron cycle and oxidative stress in the lung. Free Radic Biol Med 2004; 36: 850-857.
21. WANG X, GHIO A, YANG F, DOLAN KG, GARRICK M, PIANTADOSI C. Iron uptake and Nramp2/DMT1/DCT1 in human epithelial cells. Am J Physiol Lung Cell Mol Physiol 2002; 282: L987-L995.
22. GHIO A, CARTER J, RICHARDS J, BRIGHTON L, LAY J, DELVIN R. Disruption of normal iron homestasis after bronchial instillation of an iron-containing particle. Am J Physiol 1998; 274: L396-L403.
23. RITTER C, DACUNHA AA, ISABER C, ADRADES M, REINKE A, LUCCHIARI N, ROCHA J, STRECK EL, MENNA-BARRETO S, MOREIRA JC, DAL-PIZZOL F. Effects of N-acetylcysteine plus deferoxamine in lipopolysaccharide-induced acute lung injury in the rat. Crit Care Med 2006; 34: 471-477.
24. DEBOER DA, CLARK RE. Iron chelation in myocardial preservation after ischemia-reperfusion injury: the importance of pretreatment and toxicity. Ann Thorac Surg 1992; 53: 412-418.
25. DROSSOS G, LAZOU A, PANAGOPOULOS P, WESTABY S. Deferoxamine cardioplegia reduces superoxide radical production in human myocardium. Ann Thorac Surg 1995; 59: 169-172.
26. LALONDE C, IKEGANI K, DEMLING R. Aerosolized deferoxamine prevents lung and systemic injury caused by smoke inhalation. J Appl Physiol 1994; 77: 2057-2064.
27. NAKAMURA T, KEEP R, HUA Y, SCHALLERT T, HOFF J, XI G. Deferoxamine-induced attenuation of brain edema and neurological deficits in a rat model of intracerebral hemorrhage. Neurosurg Focus 2003; 15: 1-7.
28. PARASKEVAIDIS L, LLIODROMITIS EK, VLAHAKOS D, TSIAPRAS D, NIKOLAIDIS A, MARATHIAS A, MICHAUS A, KREMASTINOS DT. Deferoxamine infusion during coronary artery bypass grafting ameliorates lipid peroxidation and protects the myocardium against reperfusion injury: immediate and long-term significance. Eur Heart J 2005; 26: 263-270.
29. STUMPF J. Deferasirox. Am J Health-Syst Pharm 2007; 64: 606-616.
30. VICHINSKY E, ONYEKWERE O, PORTER J, SWERDLOW P, ECKMAN J, LANE P, FILES B, HASSELL K, KELLY P, WILSON F, BERNAUDIN F, FORNI GL, OKPALA I, RESSAYRE-DJAFFER C, ALBERTI D, HOLLAND J, MARKS P, FUNG E, FISCHER R, MUELLER BU, COATES T; DEFERASIROX IN SICKLE CELL INVESTIGATORS. A randomized comparison of deferasirox versus deferoxamine for the treatment of transfusional iron overload in sickle cell disease. Br J Haematol 2007; 136: 501-508.
31. VANORDEN H, HAGEMANN T. Deferasirox. An oral agent for chronic iron overload. Ann Pharmacother 2006; 40: 1110-1117.
32. KONTOGHIOGHES GJ, KOLNAGOU A, PENG CT, SHAH SV, AESSOPOS A. Safety issues of iron chelation therapy in patients with normal range iron stores including thalassaemia, neurodegenerative, renal and infectious diseases. Expert Opin Drug Saf 2010; 9: 201-206.
33. LEVINE RL, WILLIAMS J, STADTMAN ER, SHACTER E. Carbonyl assays for determination of oxidatively modified proteins. Method Enzymol 1994; 233: 346-357.
34. BRADFORD M. A rapid and sensitive for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976; 72: 248-254.
35. MATEOS F, BROCK J, PEREZ-ARELLANO J. Iron metabolism in the lower respiratory tract. Thorax 1998; 53: 594-600.
36. SHAH M, BRY K, HALLMAN M. Protective effect of exogenous transferrin against hyperoxia: A study on premature rabbits. Pediatr Pulmonol 1997; 24: 429-437.
37. YANG F, COALSON J, BOBB H, CARTER J, BANU J, GHIO A. Resistance of hypotransferrinemic mice to hyperoxia-induced lung injury. Am J Physiol Lung Cell Mol Physiol 1999; 277: 1214-1223.
38. COOKE MS. Oxidative DNA damage: mechanisms, mutation, and disease. FASEB J 2003; 17: 1195-1214.
39. DEAN RT, FU S, STOCKER R, DAVIES MJ. Biochemistry and pathology of radical-mediated protein oxidation. Biochem J 1997; 324: 1-18.
40. CARPENTER CT, PRICE PV, CHRISTMAN BW. Exhaled breath condensate isoprostanes are elevated in patients with acute lung injury or ARDS. Chest 1998; 114: 1653-1659.
41. HERSHKO CH. Control of disease by selective iron depletion: a novel therapeutic strategy utilizing iron chelators. Bailliere Clin Haematol 1994; 7: 965-1000.
42. MENASCHE P, GROUSSET C, GAUDUEL Y, MOUAS C, PIWNICA A. Prevention of hydroxyl radical formation: a critical concept for improving cardioplegia. Protective effect of deferoxamine. Circulation 1987; 76(5 pt 2): V180-V185.
43. PINHO R, SILVERIA P, SILVA L, STRECK E, DAL-PIZZOL F, MOREIRA J. N-acetylcysteine and deferoxamine reduce pulmonary oxidative stress and inflammation in rats after coal dust exposure. Environ Res 2005; 99: 355-360.
44. PIGA A, GALALLENO R, FOMI GL, CAPPELLINI M, ORIGA R, ZAPPU A, DONATO G, BORDONE E, LAVAGETTO A, ZANABONI L, SECHAUD R, HEWSON N, FORD JM, OPITZ H, ALBERTI D. Randomized phase II trial of deferasirox (Exjade®, ICL670), a once-daily, orally-administered iron chelator, in comparison to deferoxamine in thalassemia patients with transfusional iron overload. Hematologica 2006; 91: 873-880.
45. CAPPELLINI MD, TAHER A. Deferasirox (Exjade) for the treatment of iron overload. Acta Haematol 2009; 122: 165-173.
46. PIGA A. Comparative effects of deferiprone and deferoxamine on survival and cardiac disease in patients with thalassemia major: a retrospective analysis. Haematologica 2003; 88: 489-496.